Regeneron Pharmaceuticals (REGN) Revenue (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Revenue of $4.3 billion for Q2 2026, up 16.73% year-over-year from $3.7 billion in Q2 2025, and up 19.01% quarter-over-quarter from $3.6 billion in Q1 2026.
Regeneron Pharmaceuticals (REGN) Revenue (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Revenue history runs 18 years deep, the most recent figure standing at $4.3 billion for Q2 2026.
- In Q2 2026, Revenue rose 16.73% year-over-year to $4.3 billion; the TTM figure through Jun 2026 stood at $15.5 billion (up 9.29% YoY), while the FY2025 annual figure was $14.3 billion, up 0.99% from the prior year.
- Revenue for Q2 2026 stood at $4.3 billion, up from $3.6 billion in the prior quarter.
- The five-year high for Revenue was $4.3 billion in Q2 2026, with the low at $50.0 million in Q1 2022.
- The 5-year median for Revenue is $3.4 billion (2023), against an average of $3.1 billion.
- The sharpest annual moves came in 2022 and 2023: Revenue sank 98.02% in 2022, then soared 6224.2% in 2023.
- Regeneron Pharmaceuticals' Revenue stood at $100.0 million in 2022, then jumped by 3334.3% to $3.4 billion in 2023, then rose by 10.33% to $3.8 billion in 2024, then rose by 2.51% to $3.9 billion in 2025, then grew by 10.46% to $4.3 billion in 2026.
- Business Quant data shows REGN's Revenue at $4.3 billion in Q2 2026, $3.6 billion in Q1 2026, and $3.9 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 1.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.29 Bn |
| Mar 31, 2026 | 3.61 Bn |
| Dec 31, 2025 | 3.88 Bn |
| Sep 30, 2025 | 3.75 Bn |
| Jun 30, 2025 | 3.68 Bn |
| Mar 31, 2025 | 3.03 Bn |
| Dec 31, 2024 | 3.79 Bn |
| Sep 30, 2024 | 3.72 Bn |
| Jun 30, 2024 | 3.55 Bn |
| Mar 31, 2024 | 3.15 Bn |
| Dec 31, 2023 | 3.43 Bn |
| Sep 30, 2023 | 3.36 Bn |
| Jun 30, 2023 | 3.16 Bn |
| Mar 31, 2023 | 3.16 Bn |
| Dec 31, 2022 | 100.00 Mn |
| Sep 30, 2022 | 2.94 Bn |
| Jun 30, 2022 | 2.86 Bn |
| Mar 31, 2022 | 50.00 Mn |
| Dec 31, 2021 | 4.95 Bn |
| Sep 30, 2021 | 3.45 Bn |